New Drugs from Abbvie, Gilead, Intercept and Merck forecast to achieve blockbuster status by 2020

Thomson Reuters' annual ‘Drugs to Watch’ study spotlights seven emerging blockbusters poised to enter the market in 2016

id-10039602-1

key trend in 2016 is the continued development of more convenient fixed-dose, all-oral regimens for HIV and HCV

According to a new report from the Intellectual Property and Science business of Thomson Reuters, there are a total of seven new therapeutics currently in the new drug development pipeline that should enter the market this year and surpass $1 billion in annual sales by 2020. Two of these are projected to top $2 billion in annual sales.

These projections are detailed in the annual Drugs to Watch 2016 report, which mines pharmaceutical industry data to forecast the new therapeutics with the largest marketplace potential.

The two new drugs projected to exceed $2 billion in annual sales are: a chronic liver disease treatment from Intercept Pharmaceuticals and Sumitomo Dainippon Pharma with the chemical name obeticholic acid; and an anti-HIV-1 infection treatment from Gilead Sciences and Japan Tobacco which combines the chemicals emtricitabine and tenofovir alafenamide. A key trend in 2016 is the continued development of more convenient fixed-dose, all-oral regimens for HIV and HCV (Hepatitis C).

The analysis spotlights the following seven potential blockbusters, ranked by highest sales forecasts:

 Ranking (By highest sales forecast for 2020)  Drug  Disease  Pharmaceutical company  2020 forecast sales ($ billions)
 1  obeticholic acid  chronic liver diseases  Intercept Pharmaceuticals and Summitomo Dainippon Pharma  2.621
 2

 Emtricitabine+tenofir

 

Previous 1 3 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

GST

GST: Boon or Bane for Healthcare?

Send this article by email

X